Zydus Lifesciences Limited Press Release Feb 26 2024
Filed with NSE · · 2 pages · English
Summary by 6ix AI
Zydus Lifesciences Limited has announced that it received WHO prequalification for Miltefosine, a key drug for treating Leishmaniasis, also known as Kala Azhar. This approval will facilitate greater global access to the drug, which is crucial for treating a disease that affects some of the world's poorest populations. The press release highlights the significance of this milestone in combating Leishmaniasis, which has severe health implications if left untreated.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release Feb 16 2024
- Press Release Feb 09 2024
- Press Release Feb 08 2024
- Press Release Jan 30 2024
- Press Release Jan 25 2024
Later from Zydus Lifesciences
- Press Release Mar 13 2024
- Press Release Mar 14 2024
- Press Release Mar 16 2024
- Press Release Mar 23 2024
- Press Release Apr 01 2024
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences